FERRARESE, Mattia
 Distribuzione geografica
Continente #
NA - Nord America 2.463
AS - Asia 1.563
EU - Europa 861
SA - Sud America 238
AF - Africa 27
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.155
Nazione #
US - Stati Uniti d'America 2.401
SG - Singapore 607
CN - Cina 452
IT - Italia 238
BR - Brasile 204
DE - Germania 156
HK - Hong Kong 146
VN - Vietnam 98
GB - Regno Unito 74
PL - Polonia 71
ID - Indonesia 63
TR - Turchia 59
UA - Ucraina 59
FI - Finlandia 46
RU - Federazione Russa 45
SE - Svezia 37
CA - Canada 31
FR - Francia 29
JP - Giappone 28
MX - Messico 28
IN - India 21
CZ - Repubblica Ceca 17
AR - Argentina 16
BE - Belgio 15
PK - Pakistan 15
ES - Italia 13
NL - Olanda 13
IR - Iran 12
ZA - Sudafrica 12
BD - Bangladesh 11
NO - Norvegia 10
EC - Ecuador 9
AT - Austria 8
IQ - Iraq 8
KR - Corea 6
LT - Lituania 6
MY - Malesia 6
PT - Portogallo 6
IL - Israele 5
DK - Danimarca 4
GE - Georgia 4
IE - Irlanda 4
KE - Kenya 4
MA - Marocco 4
CL - Cile 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DZ - Algeria 2
JO - Giordania 2
LK - Sri Lanka 2
NP - Nepal 2
RO - Romania 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
EG - Egitto 1
EU - Europa 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MU - Mauritius 1
OM - Oman 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 5.155
Città #
Singapore 366
Ashburn 270
Chandler 212
Fairfield 195
Santa Clara 173
Beijing 155
Hong Kong 141
Woodbridge 131
Ferrara 112
Dallas 111
Seattle 90
New York 79
Houston 77
Wilmington 71
Warsaw 68
Cambridge 67
Ann Arbor 64
Los Angeles 63
Munich 57
Jakarta 55
Izmir 46
Jacksonville 43
Princeton 43
Shanghai 42
Nanjing 37
Dearborn 34
Ho Chi Minh City 34
Helsinki 32
Milan 27
São Paulo 25
Bremen 22
Hanoi 21
Tokyo 19
Denver 16
Mexico City 15
Moscow 15
Nanchang 15
Brooklyn 14
Brno 13
Chicago 13
Falkenstein 12
Guangzhou 12
London 12
Poplar 12
Redwood City 12
San Diego 12
Toronto 12
Boardman 11
Montreal 11
Orem 11
The Dalles 11
Atlanta 10
Brussels 10
Dong Ket 10
Lahore 10
Shenyang 10
Bologna 9
Hebei 9
Johannesburg 9
Phoenix 9
Rio de Janeiro 9
Rome 9
Jiaxing 8
Frankfurt am Main 7
Oslo 7
Tianjin 7
Turku 7
Zhengzhou 7
Fairford 6
Kunming 6
Manchester 6
Piemonte 6
San Francisco 6
Andover 5
Boston 5
Da Nang 5
Ferrara di Monte Baldo 5
Indore 5
Jinan 5
Nuremberg 5
Ribeirão Preto 5
San Mateo 5
Stockholm 5
Washington 5
Belo Horizonte 4
Brasília 4
Cagliari 4
Campinas 4
Castagnole delle Lanze 4
Changsha 4
Chennai 4
Columbus 4
Copenhagen 4
Curitiba 4
Des Moines 4
Erlangen 4
Florence 4
Krasnodar 4
Louvain 4
New Haven 4
Totale 3.507
Nome #
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 261
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 235
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 203
Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics 191
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 183
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 178
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 174
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 168
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 153
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 150
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 149
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 141
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 137
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 137
Protein engineering and pharmacological approaches to develop novel treatment strategies for coagulation disorders 133
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 130
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 129
A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I 129
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 129
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 129
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 128
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 127
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 126
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 125
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 124
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 118
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 114
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 113
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 111
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 105
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 105
An advanced method for the small-scale production of high-quality minicircle DNA 103
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 100
Next generation factor VIIa with enhanced half-life 95
null 93
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 91
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 84
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains 73
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association 69
Suppression of “leaky” nonsense mutations by ribosome readthrough accounts for residual factor IX levels in Haemophilia B patients 61
Totale 5.304
Categoria #
all - tutte 27.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.628


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021339 0 0 0 0 0 38 58 60 25 66 51 41
2021/2022358 59 35 8 4 21 22 5 12 17 31 21 123
2022/2023436 48 61 12 62 62 50 30 31 42 5 18 15
2023/2024285 10 23 16 4 17 61 15 30 6 9 12 82
2024/20251.124 36 20 97 29 130 167 20 23 178 103 181 140
2025/20261.644 299 181 229 415 460 60 0 0 0 0 0 0
Totale 5.304